STF 083010

IRE1α endonuclease inhibitor CAS# 307543-71-1

STF 083010

Catalog No. BCC6209----Order now to get a substantial discount!

Product Name & Size Price Stock
STF 083010: 5mg $35 In Stock
STF 083010: 10mg Please Inquire In Stock
STF 083010: 20mg Please Inquire Please Inquire
STF 083010: 50mg Please Inquire Please Inquire
STF 083010: 100mg Please Inquire Please Inquire
STF 083010: 200mg Please Inquire Please Inquire
STF 083010: 500mg Please Inquire Please Inquire
STF 083010: 1000mg Please Inquire Please Inquire
Related Products
  • SU5416

    Catalog No.:BCC1974
    CAS No.:204005-46-9
  • CH 223191

    Catalog No.:BCC3896
    CAS No.:301326-22-7

Quality Control of STF 083010

Number of papers citing our products

Chemical structure

STF 083010

3D structure

Chemical Properties of STF 083010

Cas No. 307543-71-1 SDF Download SDF
PubChem ID 6537512 Appearance Powder
Formula C15H11NO3S2 M.Wt 317.38
Type of Compound N/A Storage Desiccate at -20°C
Solubility DMSO : 100 mg/mL (315.08 mM; Need ultrasonic)
H2O : < 0.1 mg/mL (insoluble)
Chemical Name N-[(Z)-(2-oxonaphthalen-1-ylidene)methyl]thiophene-2-sulfonamide
SMILES C1=CC=C2C(=C1)C=CC(=O)C2=CNS(=O)(=O)C3=CC=CS3
Standard InChIKey AUXKGDNZANYAPX-RAXLEYEMSA-N
Standard InChI InChI=1S/C15H11NO3S2/c17-14-8-7-11-4-1-2-5-12(11)13(14)10-16-21(18,19)15-6-3-9-20-15/h1-10,16H/b13-10-
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Biological Activity of STF 083010

DescriptionInhibitor of IRE1α endonuclease activity; blocks endogenous XBP1 mRNA splicing. Displays cytostatic and cytotoxic effects in CD138+ multiple myeloma (MM) cells in vitro; inhibits bortezomib-induced XBP1 activity in myeloma xenografts in vivo. Does not alter IRE1α kinase activity.

STF 083010 Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

STF 083010 Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of STF 083010

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 3.1508 mL 15.754 mL 31.508 mL 63.0159 mL 78.7699 mL
5 mM 0.6302 mL 3.1508 mL 6.3016 mL 12.6032 mL 15.754 mL
10 mM 0.3151 mL 1.5754 mL 3.1508 mL 6.3016 mL 7.877 mL
50 mM 0.063 mL 0.3151 mL 0.6302 mL 1.2603 mL 1.5754 mL
100 mM 0.0315 mL 0.1575 mL 0.3151 mL 0.6302 mL 0.7877 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University

Background on STF 083010

IC50: N/A

STF 083010 is an inhibitor of IRE1α endonuclease activity, and does not alter IRE1α kinase.

In vitro: After endoplasmic reticulum stress both in vitro and in vivo, STF-083010 prevented Ire1 endonuclease activity without affecting its kinase activity. Treatment with STF-083010 exhibited significant antimyeloma activity in model human MM xenografts. Similarly, compared with other similarly isolated cell populations, STF-083010 was preferentially toxic to freshly isolated human CD138 MM cells. On basis of the identification of this novel Ire1 inhibitor, propose that the Ire1-XBP1 axis is a promising target for anticancer therapy (especially in the context of MM) [1].

In stark contrast, when apoptosis of tumor cells desired, therapeutic strategies attempted to stimulate ER stress with the aim of killing cancerous cells in the case of cancer treatment. For example, it enhanced the killing of these cancer cells that exposure of human multiple myeloma cells to STF083010, and that or treatment of a human pancreatic cancer cell line with bortezomib, [2].

In vivo: The small molecule STF083010, identified by a high-throughput screen of compounds affecting IRE1 activity, was capable of directly inhibiting the endonuclease function of IRE1 without affecting its kinase activity. After treatment of mice harboring subcutaneous xenografts led to tumor shrinkage and multiple myeloma cells harvested from cancer patients died following exposure to STF083010, the antimyeloma therapeutic potential of STF083010 was convincingly demonstrated [2].

Clinical trial: So far, no clinical study has been conducted.

References:
[1].  Papandreou I, Denko NC, Olson M, Van Melckebeke H, Lust S, Tam A, Solow-Cordero DE, Bouley DM, Offner F, Niwa M, Koong AC. Identification of an Ire1alpha endonuclease specific inhibitor with cytotoxic activity against human multiple myeloma. Blood. 2011 Jan 27; 117 (4):1311-4.
[2].  Kraskiewicz H, FitzGerald U. InterfERing with endoplasmic reticulum stress. Trends Pharmacol Sci. 2012 Feb; 33 (2):53-63.

Featured Products
New Products
 

References on STF 083010

A novel chemical, STF-083010, reverses tamoxifen-related drug resistance in breast cancer by inhibiting IRE1/XBP1.[Pubmed:26517687]

Oncotarget. 2015 Dec 1;6(38):40692-703.

Recent studies show that the unfolded protein response (UPR) within the endoplasmic reticulum is correlated with breast cancer drug resistance. In particular, human X-box binding protein-1(XBP1), a transcription factor which participates in UPR stress signaling, is reported to correlate with poor clinical responsiveness to tamoxifen. In this study, we develop a tamoxifen-resistant MCF-7 cell line by treating the cell line with low concentration of tamoxifen, and we find that XBP1 is indeed up-regulated at both the mRNA and protein levels compared to normal MCF-7 cells. STF-083010, a novel inhibitor which specifically blocks the XBP1 splicing, reestablishes tamoxifen sensitivity to resistant MCF-7 cells. Moreover, co-treatment with STF-083010 and tamoxifen can significantly delay breast cancer progression in a xenograft mammary tumor model. We next investigate the expression of XBP1s in over 170 breast cancer patients' samples and the results demonstrate that XBP1s expression level is highly correlated with overall survival in the ER+ subgroup, but not in the ER- subgroup, suggesting a potential therapeutic application of XBP1 inhibitors in ER+breast cancer treatment.

InterfERing with endoplasmic reticulum stress.[Pubmed:22112465]

Trends Pharmacol Sci. 2012 Feb;33(2):53-63.

Stress to the endoplasmic reticulum (ER) is a recognized factor in Alzheimer's and Parkinson's diseases, diabetes, heart disease, liver disorders and cancer. Thus, drugs that interfere with ER stress have wide therapeutic potential. Here we review the effects of drugs on three arms of ER stress: the protein kinase RNA-activated (PKR)-like ER kinase (PERK) arm, the activated transcription factor 6 (ATF6) arm and the inositol-requiring enzyme 1 (IRE1) arm. Drugs fall into five groups: (i) compounds directly binding to ER stress molecules; (ii) chemical chaperones; (iii) inhibitors of protein degradation; (iv) antioxidants; (v) drugs affecting calcium signaling. Treatments are generally inhibitory and lead to increased viability, except when applied to cancer cells. A focus on interfering with the ATF6 arm is required, and more in vivo testing of these compounds concurrently across all three arms is needed if the full importance of ER stress to human disease is to be realized.

Identification of an Ire1alpha endonuclease specific inhibitor with cytotoxic activity against human multiple myeloma.[Pubmed:21081713]

Blood. 2011 Jan 27;117(4):1311-4.

Activation of the adaptive Ire1-XBP1 pathway has been identified in many solid tumors and hematologic malignancies, including multiple myeloma (MM). Here, we report the identification of STF-083010, a novel small-molecule inhibitor of Ire1. STF-083010 inhibited Ire1 endonuclease activity, without affecting its kinase activity, after endoplasmic reticulum stress both in vitro and in vivo. Treatment with STF-083010 showed significant antimyeloma activity in model human MM xenografts. Similarly, STF-083010 was preferentially toxic to freshly isolated human CD138(+) MM cells compared with other similarly isolated cell populations. The identification of this novel Ire1 inhibitor supports the hypothesis that the Ire1-XBP1 axis is a promising target for anticancer therapy, especially in the context of MM.

Description

STF-083010 is a specific IRE1α inhibitor. STF-083010 inhibits Ire1 endonuclease activity, without affecting its kinase activity, after endoplasmic reticulum stress.

Keywords:

STF 083010,307543-71-1,Natural Products,Cholinesterases, buy STF 083010 , STF 083010 supplier , purchase STF 083010 , STF 083010 cost , STF 083010 manufacturer , order STF 083010 , high purity STF 083010

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: